important limitation of these studies is that conclusions are based only on subjects with MDD, while in the DSM-IV-TR, atypical features can occur in individuals with either depressive or bipolar disorders (BDs). Atypical depression may be different in BD, compared with MDD. Studies by Benazzi (4) and Angst and others (5) found atypical features to be much more common in BD II than in MDD, which accords with the official DSM-IV-TR statement (p 421). In the Benazzi study of consecutively presenting outpatients, atypical features were present in 53.5% of subjects with BD II (n = 241) and in 23.7% of subjects with MDD (n = 164) (z = 5.9, P = 0.0000) (4) . These 2 studies have an important difference from the Parker and others (1) and Posternak and Zimmerman (3) studies: they include mixed samples (that is, BD II plus MDD). Benazzi found significant associations among atypical symptoms (4). However, while most atypical symptoms were significantly associated in Benazzi's BD II sample, only a few were significantly associated in his MDD sample. This suggests that atypical depression may differ in depressive and bipolar disorders (6) . Angst and others also found significant associations among atypical symptoms (5) , but in the Angst and others study, atypical depression was not studied separately in the BD II and MDD sample (which were combined in the analyses). Parker and others (1), Posternak and Zimmerman (3), and Angst and others (5) concluded that mood reactivity should not have the priority it has in DSM-IV-TR (according to which it must always be present). Benazzi (4) came to the same conclusion, but only for the MDD sample. In the BD II sample, mood reactivity was significantly associated with atypical symptoms, and depression patients with mood reactivity had significantly more atypical symptoms than did depression patients without mood reactivity. These findings support the inclusion of mood reactivity among the atypical features in BD II but not in MDD. Consequently, atypical depression should probably be studied independently in MDD and in BDs. Parker and others stated that hypothesizing a different response to antidepressants to support the diagnostic validity of atypical features (currently its main validator) is an unusual approach (1). Family history is a more important diagnostic validator (6, 7) . It has been shown that atypical features are strongly associated with a positive family history of BD (8)-a finding further supporting the distinction between atypical depression in MDD and in BD. Further studies are required to find a new definition of atypical depression, beyond that offered in the DSM-IV-TR.
Franco Benazzi, MD Forli, Italy

Potential Risk of Diabetes Mellitus With the Use of Atypical Antipsychotic Medication
Dear Editor:
For the past 10 years, several atypical antipsychotics have been used to alleviate the symptoms of psychosis in a diverse patient population suffering from schizophrenia. During this time, clinicians have encountered benefits as well as a host of side effects in this patient population. Weight gain and the development or exacerbation of diabetes mellitus (DM) continue to be serious issues that have forced clinicians to vigilantly follow up their patients' metabolic profile to prevent serious consequences.
The following case illustrates the need to monitor individual patients, not only for improvement of psychosis but also for DM as an adverse side effect.
Case Report
Mr B, aged 62 years, is an African American who has suffered from schizophrenia for more than 45 years and was hospitalized owing to exacerbated symptoms of psychosis. He had no history of comorbid substance abuse. He had been free of diabetes, and his family history is negative for DM. His body weight was in the normal range for his age and height, and there had been no dietary changes. Hemoglobin A1c was within normal range. He was started on olanzapine, and the dosage titrated to 20 mg within a few days. His psychotic symptoms began to decrease in intensity, although they had not fully resolved after about 14 days. At this time, his blood glucose rose to almost 200 mg and remained high, requiring an oral hypoglycemic agent. Because of his severe psychotic illness, he was started on ziprasidone, a novel antipsychotic used to treat psychosis, in the hope of gradually weaning him off olanzapine. His blood glucose levels are now back to normal. With the combination of ziprasidone titrated to the optimal dosage of 80 mg twice daily and olanzepine 20 mg at bedtime, his psychosis is well controlled, and he can be discharged in the near future. However, the emergence of DM remains a serious issue in this patient. The rest of his laboratory tests remain normal at this stage.
Discussion
The mechanism for antipsychoticinduced DM is not clear in this case. There was no weight gain during his short period of hospitalization. We hope that over time the antipsychotic crossover will continue to effectively treat his psychosis and that his blood glucose will revert to its pretreatment level, so that the oral hypoglycemic agent can be safely discontinued.
Several retrospective data analyses of patients with diabetes taking antipsychotics have yielded an increased risk of either development or exacerbation of this metabolic condition-up to 3 times the risk with olanzapine, 7 times the risk with clozapine, and 2 times the risk with conventional high-potency antipsychotics (1) .
Therefore, careful and regular monitoring for diabetes pre-and posttreatment continues to remain a significant part of the psychopharmacotherapy of schizophrenia. The availability of newer antipsychotics such as ziprasidone and aripiprazole may be a step forward in managing this situation. 
Clozapine-Induced Aplastic Anemia in a Patient With Parkinson's Disease
Psychosis is a common complication of the drug treatment of Parkinson's disease (occurring in approximately 25% of patients) and therefore constitutes a serious public health problem. All patients suffering from idiopathic Parkinson's disease, and especially elderly patients with dementia, are at risk of developing delusions or hallucinations. The most prominent psychotogenic factors are dopaminomimetic agents, which may induce dopamine hypersensitivity in the frontal and limbic dopamine projection regions and consequently, either directly or indirectly, elicit psychotic signs and symptoms (1) . A Parkinson's disease-related cholinergic deficit combined with an age-related further loss of cholinergic integrity also plays a prominent role (1) . Treating this complication is difficult: because of their selective dopamine receptor antagonistic effects, most typical antipsychotic drugs worsen motor symptoms of Parkinson's disease. As a consequence of a nonselective antagonism at both serotonergic and dopaminergic receptors, atypical antipsychotics such as clozapine or olanzapine are associated with fewer extrapyramidal side effects (2) . Clozapine was the first atypical antipsychotic drug to be introduced into clinical use in several European countries, in the late 1960s (3) . Clozapine treatment is associated with wide side effects that include the following: blood-cell dyscrasias, benign granulocytopenia, transient granulocytosis, and a risk of agranulocytosis as high as 0.5% to 1% (4); transient fever in up to 50% of the patients; sedation; and considerable body-weight gain. The mechanisms underlying these side effects are still unknown, but recent data suggest that the metabolism of clozapine and its immunomodulatory effects may play a role. Aplastic anemia in all its features emerging during clozapine therapy has not been documented in the literature. We present a case of clozapine-induced aplastic anemia.
Case Report
A 53-year-old man with Parkinson's disease (according to ICD-10 criteria) developed a dopamine-induced psychosis with hallucinations. Because of his persisting psychotic symptoms, he was admitted to a psychiatric hospital, and antipsychotic pharmacotherapy of 50 mg clozapine daily was started. He developed fever after 1 week, and his blood tests revealed abnormalities (neutrophil count < 500/L, platelet count 93 000/L, and reticulocyte count < 20 000/L). Clozapine therapy was discontinued and he was admitted to our clinic. According to the criteria of the International Aplastic Anemia Study Group, we diagnosed a severe form of drug-induced aplastic anemia (neutrophil count < 500/L, platelet count 89 000/L, and reticulocyte count < 20 000/L). He received blood transfusions, and we started therapy with hematopoietic growth factors (r-metHuG-CSF) (5) and
antibiotics. The Parkinson's disease was treated with dopamine and apomorphine. After 14 days, he was responding to the therapy, and the aplastic anemia disappeared. The psychosis with delusions and hallucinations was still evident, and we established a neuroleptic therapy with quetiapine. The therapy with hematopoietic growth factors was discontinued.
